About Contact Us Careers

Polycystic Kidney Disease Drugs Market Size and Forecast, by Type {Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD)}, by Treatment (Medication, Surgery), Diagnosis (Ultrasound, CT Scan, MRI Scan), End-user (Hospitals, Specialty Clinics) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4323
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT

Polycystic Kidney Disease Drugs Market Outlook:

Polycystic Kidney Disease Drugs Market size was over USD 571.38 million in 2025 and is projected to reach USD 1.1 billion by 2035, witnessing around 6.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of polycystic kidney disease drugs is evaluated at USD 606.35 million.

Polycystic-Kidney-Disease-Drugs-Market-scope
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the market can be attributed to the worldwide increasing incidence of chronic kidney diseases, resulting in death and serious medical issues. In accordance with the Centers for Disease Control and Prevention, a total of 37 million Americans are estimated to have chronic kidney disease, which is 15% of the region's population.  Further, the growing prevalence of hypertension, and surging research and development activities for the development of chronic kidney disease drugs are some further factors that are anticipated to massively drive the market’s growth further over the projected time frame.

In addition to these, factors that are believed to fuel the market growth of polycystic kidney disease drugs include the rise in PKD drug trials, followed by the growth in the approval of novel drugs by the government, along with the development of a wide range of medications by key players are anticipated to expand the global polycystic kidney disease drugs market size during the forecast period. For instance, Reata Pharmaceuticals, Inc. announced positive phase II results for bardoxolone methyl in chronic renal disease caused by Alport syndrome and autosomal dominant polycystic kidney disease in July 2018. Additionally, growing awareness about kidney diseases among people is also predicted to present the potential for market expansion over the projected period.

Key Polycystic Kidney Disease Drugs Market Insights Summary:

  • Regional Highlights:

    • North America is projected to hold the majority revenue share by 2035 in the polycystic kidney disease drugs market, supported by rising per capita income and heightened awareness of early diagnosis.
    • The Asia Pacific region is expected to record notable growth by 2035, owing to the escalating prevalence of chronic kidney disorders.

  • Segment Insights:

    • The autosomal dominant polycystic kidney disease (ADPKD) segment is anticipated to secure the largest share by 2035 in the polycystic kidney disease drugs market, reinforced by the increasing global incidence of ADPKD.
    • The hospitals segment is projected to garner a significant share by 2035, attributed to the rising PKD patient pool requiring dialysis-based treatments.

  • Key Growth Trends:

    • The Surge in the Incidence of Autosomal Dominant Polycystic Kidney Diseases (ADPKD)
    • Growing Initiatives to Raise Awareness About PKDs

  • Major Challenges:

    • Insufficient Number of Approved Drugs
    • Strict Government Guidelines for Drug Trials

  • Key Players: Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics, Inc., Taro Pharmaceutical Industries Ltd., GlaxoSmithKline plc.

Global Polycystic Kidney Disease Drugs Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 571.38 million
    • 2026 Market Size: USD 606.35 million
    • Projected Market Size: USD 1.1 billion by 2035
    • Growth Forecasts: 6.8%

  • Key Regional Dynamics:

    • Largest Region: North America (Majority Revenue Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: India, Brazil, South Korea, Mexico, Indonesia

    • Last updated on : 21 November, 2025

Growth Drivers

  • The Surge in the Incidence of Autosomal Dominant Polycystic Kidney Diseases (ADPKD) - ADPKD is a rare condition, as it contributes significantly to chronic kidney disease and kidney failure. In addition, polycystic kidney disease, the most common chronic kidney disease, substantially increases the prevalence of chronic kidney disease. As a result, an increasing prevalence of ADPKD is expected to drive global polycystic kidney disease drugs market growth over the forecast period. For instance, around 200,000 to 500,000 people in the United States and another 13,000,000 people around the world suffer from ADPKD, and only about 25% of the population is aware of the disease.

  • Growing Initiatives to Raise Awareness About PKDs - For instance, PKD Foundation is the only non-profit in the U.S. exclusively dedicated to treating and curing polycystic kidney disease. Over 1,300 research studies were funded and USD 1.5 billion in research funding has been leveraged.

  • Increasing Healthcare Spending Worldwide - According to the Centers for Medicare & Medicaid Services, the United States spent USD 4.1 trillion on healthcare services in 2020, representing 19.7% of the GDP.

  • Rising Number of Research and Development Activities - According to the World Bank, the number of researchers in R&D activities has increased from 14,12 researchers per million in 2015 to 1,597 researchers per million in 2018.

  • Growth in Personal Disposable Income - According to the Bureau of Economic Analysis, in the United States, personal income increased by USD 47.0 billion (0.2%) in July 2020, and disposable personal income expanded by USD 37.6 billion (0.2%).

Challenges

  • Insufficient Number of Approved Drugs - There are a few drugs available to treat polycystic kidney disease, and researchers are still working to discover more medicines and drugs for the effective treatment of the disease. Hence, this factor is considered to be one of the major restraints for the market in the coming years.

  • Strict Government Guidelines for Drug Trials

  • High Expenses Associated with Treatment

Polycystic Kidney Disease Drugs Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

6.8%

Base Year Market Size (2025)

USD 571.38 million

Forecast Year Market Size (2035)

USD 1.1 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Polycystic Kidney Disease Drugs Market Segmentation:

Type {Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD)}

The global polycystic kidney disease drugs market is segmented and analyzed for demand and supply by type into autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and others. Out of the three types of segments, the autosomal dominant polycystic kidney disease (ADPKD) segment is anticipated to capture the largest market size in the global polycystic kidney disease drugs market over the projected time frame. The growth of the segment can be attributed to the worldwide increasing incidence of autosomal dominant polycystic kidney diseases. For instance, it was observed that the prevalence of ADPKD is estimated to be somewhere between 1 in 500-1,000 among the general population. Each year, about 5,900 new cases are recorded in the United States. Besides this, escalating approval of the novel drugs is also anticipated to propel the segment growth over the projected time frame. 

End-user (Hospitals, Specialty Clinics) 

The global polycystic kidney disease drugs market is also segmented and analyzed for demand and supply by the end user into hospitals, specialty clinics, and others. Amongst these three segments, the hospitals segment is expected to garner a significant share owing to the fact that patients suffering from polycystic kidney disease often visit hospitals for treatments such as hemodialysis and peritoneal dialysis. Therefore, an increase in the PKD patient pool is anticipated to fuel the segment growth, along with the adequacy of favorable reimbursement policies in developed nations, is estimated to drive the growth of the segment over the forecast period.  On the other hand, the specialty clinics segment is projected to witness a notable CAGR during the forecast period, owing to the rising awareness of this disease amongst people across the globe. The growing inclination of patients towards early diagnosis and treatment of polycystic kidney disease is also propelling the demand for quality treatment. This, as a result, is projected to generate numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments:

                  By Type

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  • Others

                  By Treatment

  • Medication

  • Surgery

  • Others

                  By Diagnosis

  • Ultrasound

  • CT Scan

  • MRI Scan

                  By End User

  • Hospitals

  • Specialty Clinics

  • Others
 
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Polycystic Kidney Disease Drugs Market - Regional Analysis

North American Market Forecast   

North America industry is predicted to dominate majority revenue share by 2035. The growth of the market can be attributed majorly to the rise in per capita income, along with rising awareness of the early diagnosis of chronic kidney diseases as of the advancement in the medical array in the region. In accordance with data provided by the World Bank, the annual income of each individual in the United States rose by USD 69287.5 in 2021 from USD 63027.7 in the year 2020. Further, the presence of affordable healthcare policies in the region, along with intensive drug research and development, is also anticipated to contribute to the market growth in the region. In addition, a significant increase in the medical and healthcare industries, easy drug accessibility, and dynamic surge in dialysis procedures are further expected to fuel the global polycystic kidney disease drugs market in the region during the forecast period.

APAC Market Statistics

Furthermore, the Asia Pacific polycystic kidney disease drugs market is anticipated to display notable market growth by the end of 2035. The growth of the market can be attributed to the mounting proportion of chronic kidney disorders, coupled with the developing healthcare facilities in emerging nations such as China, India, and so on. For instance, in 2019, there were around 9 million new cases and nearly 783 035 fatalities owing to CKD in the Asia Pacific region. Between 1990 and 2019, the region's CKD prevalence more than doubled, rising from around 203.8 million to 433.6 million. In addition to this, the increasing initiatives by the government of nations to raise awareness about chronic kidney disorders, along with the escalating ratio of aging people, are some further factors that are anticipated to propel the market growth throughout the projected time frame in the region.

Polycystic-Kidney-Disease-Drugs-Market-regional
Get Strategic Analysis by Region Now: Request Free Sample PDF

Polycystic Kidney Disease Drugs Market Players:

    • Otsuka Pharmaceutical Co., Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Exelixis, Inc.
    • XORTX Therapeutics, Inc.
    • AstraZeneca PLC
    • Manros Therapeutics
    • Regulus Therapeutics Inc.
    • Reata Pharmaceuticals, Inc.
    • Pano Therapeutics, Inc.
    • Taro Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.

Recent Developments

  • XORTX Therapeutics Inc. declared the positive outcomes from XRX-OXY-101 (“PK Clinical Trial”). The outcomes showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.

  • Pano Therapeutics, Inc. has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio.

  • Report ID: 4323
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of polycystic kidney disease drugs is evaluated at USD 606.35 million.

The global polycystic kidney disease drugs market size was worth more than USD 571.38 million in 2025 and is poised to witness a CAGR of over 6.8%, crossing USD 1.1 billion revenue by 2035.

North America is projected to hold the majority revenue share by 2035 in the polycystic kidney disease drugs market, supported by rising per capita income and heightened awareness of early diagnosis.

Key players in the market include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics, Inc., Taro Pharmaceutical Industries Ltd., GlaxoSmithKline plc.

Polycystic Kidney Disease Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos